12:00 AM
Jan 19, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Alagebrium: Completed Phase II enrollment

Synvista completed enrollment of 102 patients in the double-blind, placebo-controlled, Dutch Phase II BENEFICIAL trial evaluating 200 mg of oral alagebrium given...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >